

Special Issue

Analysis of Vaccine-Induced Adaptive Immune Responses

Message from the Guest Editors

B and T cells play key roles in adaptive immune responses. Research into cellular immunology provides an understanding of T cell recognition, activation and dysregulation, and their roles in protecting against infectious diseases and cancer and autoimmune diseases. Similarly, studies in the field of humoral immunity are crucial to determine the roles of antibodies in providing such protection, the functionality of different immunoglobulins, and the activity of distinct B cell subsets. In recent years, new sophisticated and cutting-edge methodologies have become available, allowing us to gain insights into lymphocyte biology and functions and their mechanisms of action. These innovative techniques can represent extremely useful tools to characterize vaccine-induced cellular and humoral responses. This Special Issue focus on the advances and application of these new methodologies in studying cellular and humoral immunity against vaccine-preventable infectious diseases. We request articles and reviews on this topic, which must be focused on the keywords and explain how these studies have changed or enhanced our understanding of T cell immunity.

Guest Editors

Dr. Francesco Nicoli

Department of Chemical, Pharmaceutical and Agricultural Sciences,
University of Ferrara, 44123 Ferrara, Italy

Prof. Dr. Antonella Caputo

Department of Chemical, Pharmacological and Agricultural Sciences,
University of Ferrara, 44121 Ferrara, Italy

Deadline for manuscript submissions

closed (31 January 2026)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/185633

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).